Medical Articles 6/11

Posted by rob on June 11, 2008 under Uncategorized | Be the First to Comment

No
significance of derivative chromosome 9 deletion on the clearance
kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular
response, loss of response, or treatment failure to imatinib mesylate
therapy for chronic myeloid leukemia.

Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo.

Intermittent
Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy
and Improves Tolerability in Imatinib-Resistant and -Intolerant
Chronic-Phase Chronic Myeloid Leukemia.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.

Restoration
of insulin sensitivity following treatment with imatinib mesylate
(Gleevec) in non-diabetic patients with chronic myelogenic leukemia
(CML).

Phosphorylation
levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic
myeloid leukemia cells implicate alternative pathway usage as a
survival strategy.

Sequential
mutations causing resistance to both Imatinib Mesylate and Dasatinib in
a chronic myeloid leukaemia patient progressing to lymphoid blast
crisis.

Add A Comment

You must be logged in to post a comment.

home top